Vertex Pharmaceuticals Inc (VRTX)

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Ticker
VRTX
Exchange
Nasdaq
Sector
Healthcare
Industry
Biotechnology
Market cap
$136.34B
52-week range
$412.27 - $568.67

Valuation

Share price
$537.79 (close of Nov 16, 2026)
P/E (TTM)
34.34x
Price to book
6.52x
Price to free cash flow
42.58x
Enterprise value
$137.84B
Book value per share
$82.47

Price performance

PeriodChange
1 day-0.15%
5 days-2.37%
1 month+7.61%
3 months+6.34%
6 months+23.08%
Year to date+18.62%
1 year+23.02%
3 years+56.79%
5 years+185.56%
10 years+494.44%
All time+11,850.89%

Short interest

As of
Oct 30, 2026
Short % of float
2.14%
Shares short
4.81M
Days to cover
3.38
Change since prior report
+12.87%
Source
FINRA consolidated short interest

Members of Congress who disclosed VRTX trades

David Taylor · Jefferson Shreve · Lisa McClain · Byron Donalds · Alan Armstrong · Julia Letlow · Tommy Tuberville

Super investors holding VRTX

Ken Griffin (Citadel) · Tweedy Browne (Tweedy Browne Company LLC) · Ray Dalio (Bridgewater Associates)

Profitability and growth

Return on equity
21.18%
Return on invested capital
16.83%
Return on assets
15.42%
Return on capital employed
19.16%
Gross margin
86.24%
Net margin
32.94%
EBITDA margin
36.52%
Revenue growth
8.90%

Cash flow and balance sheet

Free cash flow yield (TTM)
2.35%
Current ratio
2.34x
Net debt to EBITDA
0.31x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
Revenue
$12.00B
Cost of revenue
$1.65B
Gross profit
$10.35B
EBITDA
$4.38B
Net income
$3.95B
Earnings per share
$15.46
Research and development
$3.91B
Interest expense
$13.30M
Shares outstanding
255.70M

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-12-31$12.00B$10.35B$3.95B$15.46
2024-12-31$11.02B$9.49B-$535.60M-$2.08
2023-12-31$9.87B$8.61B$3.62B$14.05
2022-12-31$8.93B$7.85B$3.32B$12.97
2021-12-31$7.57B$6.67B$2.34B$9.09
2020-12-31$6.21B$5.47B$2.71B$10.44
2019-12-31$4.16B$3.62B$1.18B$4.58
2018-12-31$3.05B$2.64B$2.10B$8.24
2017-12-31$2.49B$2.21B$263.48M$1.06
2016-12-31$1.70B$1.49B-$112.05M-$0.46

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-3186.24%32.94%21.18%16.83%
2024-12-3186.11%-4.86%-3.26%-1.28%
2023-12-3187.21%36.68%20.59%16.70%
2022-12-3187.90%37.20%23.88%22.93%
2021-12-3188.06%30.92%23.19%21.63%
2020-12-3188.14%43.70%31.22%25.45%
2019-12-3186.84%28.27%19.34%14.49%
2018-12-3186.56%68.80%47.28%12.69%
2017-12-3188.95%10.59%12.90%6.03%
2016-12-3187.64%-6.58%-8.37%0.37%

Cash and debt by year

Period endCash
2025-12-31$5.08B
2024-12-31$4.57B
2023-12-31$10.37B
2022-12-31$10.50B
2021-12-31$6.79B
2020-12-31$5.99B
2019-12-31$3.11B
2018-12-31$3.17B
2017-12-31$2.09B
2016-12-31$1.43B

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31$3.19B$685.90M
2024-12-31-$790.30M$698.50M
2023-12-31$3.34B$581.20M
2022-12-31$3.93B$491.30M
2021-12-31$2.41B$441.40M
2020-12-31$2.99B$429.50M
2019-12-31$1.49B$360.50M
2018-12-31$1.17B$325.05M
2017-12-31$745.52M$293.24M
2016-12-31$179.54M$240.62M

Investor relations

Past earnings dates

ReportedFiscal periodEPS estimate
2026-11-02Sep 2026$4.36
2026-08-03Jun 2026$4.15
2026-05-04Mar 2026$3.69
2026-02-12Dec 2025$4.41
2025-11-03Sep 2025$4.00
2025-08-04Jun 2025$3.74
2025-05-05Mar 2025$3.69
2025-02-10Dec 2024$3.38

Filings and sources

Company website
vrtx.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Insmed Inc (INSM) · Bio-Techne Corp (TECH) · ICON plc (ICLR) · Charles River Laboratories International, Inc. (CRL) · Revvity, Inc. (RVTY)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades